MARKET

HSTO

HSTO

Conatus Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.470
-0.040
0.00%
After Hours: 1.400 -0.07 -4.76% 17:57 09/24 EDT
OPEN
1.490
PREV CLOSE
1.470
HIGH
1.490
LOW
1.300
VOLUME
46.96K
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
1.300
MARKET CAP
17.95M
P/E (TTM)
-0.4046
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 17h ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 2d ago
Why Histogen's Stock Is Trading Higher Today
Histogen (NASDAQ: HSTO) shares are trading higher on Wednesday after the company recei
Benzinga · 09/16 18:59
Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee
Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process
GlobeNewswire · 09/16 13:00
Histogen secures $2M grant for advancement of HST-003 in knee injury
Histogen (HSTO) has been awarded a $2M grant by the U.S. Department of Defense (DoD) to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the
Seekingalpha · 09/16 12:34
Histogen Announces $2M Grant Award From Department Of Defense For Clinical Advancement Of HST-003 For Cartilage Regeneration In The Knee
Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020 SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on
Benzinga · 09/16 12:09
Histogen concludes dosing in mid-stage study of HST-001 for baldness
Histogen ([[HSTO]]) has completed patient dosing for the week 6 treatment timepoint in its Phase 1b/2a trial of HST-001 for the treatment of androgenic alopecia (pattern baldness) in men.The company remains
Seekingalpha · 09/10 16:03
Histogen Announces Completion Of Dosing Milestone In Its 1b/2a Trial For Androgenic Alopecia In Men
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural
Benzinga · 09/10 12:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSTO. Analyze the recent business situations of Conatus Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSTO stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 1.59M
% Owned: 13.06%
Shares Outstanding: 12.21M
TypeInstitutionsShares
Increased
4
127.94K
New
18
-43.66K
Decreased
7
8.14K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Director
David Crean
President/Chief Executive Officer/Director
Richard Pascoe
Founder/Chief Scientific Officer
Gail Naughton
Chief Financial Officer/Executive Vice President
Susan Knudson
Senior Vice President
Daniel Ripley
Senior Vice President
Edward Smith
Vice President - Operations
Martin Latterich
Secretary
Thomas Hubka
Director
Stephen Chang
Director
Jonathan Jackson
Director
Steven Mento
Director
Brian Satz
Director
Hayden Yizhuo Zhang
Independent Director
Daniel Kisner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HSTO
Histogen Inc., formerly Conatus Pharmaceuticals Inc., is a regenerative medicine company. The Company is focused on developing technologies that replace and regenerates tissues in the body. The company’s technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address unmet medical needs. The Company has product candidates in clinical development intended to address and offer treatment for hair loss, dermal filler and treatment for joint cartilage repair. The Company manufactures a soluble multipotent cell conditioned media (CCM), which is the starting material for products for hair growth, skin care and other applications. In addition to this, the Company also manufactures an insoluble extracellular matrix (ECM) for applications such as orthopedics, wound care and soft tissue augmentation.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Histogen Inc stock information, including NASDAQ:HSTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSTO stock methods without spending real money on the virtual paper trading platform.